NEPH Nephros Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Lobo Wesley S.	2. Issuer Name and Ticker or Trading Symbol NEPHROS INC [ NEPH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Commercial Officer
(Last)          (First)          (Middle) C/O NEPHROS, INC., 380 LACKAWANNA PLACE	3. Date of Earliest Transaction (MM/DD/YYYY) 9/1/2021
(Street) SOUTH ORANGE, NJ 07079 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								41557 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Optoin (right to buy)	$8.66							(2)	2/16/2031	Common Stock	114178		114178	D
Stock Option (right to buy)	$8.47	9/1/2021		A		57368		(3)	9/1/2031	Common Stock	57368	$0	57368	D

Explanation of Responses:
(1)	Includes (i) 20,557 shares of restricted stock for which the risk of forfeiture will lapse on 2/16/22; and (ii) 20,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/22, 2/16/23, 2/16/24 and 2/16/25.
(2)	Options to purchase 28,545 shares vest on 2/16/22 and options to purchase 85,633 shares vest quarterly in 12 equal amounts commencing on 5/16/22.
(3)	Options to purchase 14,342 shares vest on 9/1/22 and options to purchase 43,026 shares vest quarterly in 12 equal amounts commencing on 12/1/22.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Lobo Wesley S. C/O NEPHROS, INC. 380 LACKAWANNA PLACE SOUTH ORANGE, NJ 07079			Chief Commercial Officer

Signatures
/s/ Christopher Melsha as attorney-in-fact for Wesley Lobo pursuant to Power of Attorney previously filed.		9/3/2021
**Signature of Reporting Person		Date